Adempas(riociguat)
Adempas, Riociguat (riociguat) is a small molecule pharmaceutical. Riociguat was first approved as Adempas on 2013-10-08. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Adempas, Riociguat
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adempas | New Drug Application | 2023-01-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 12 | 8 | 7 | 12 | 40 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 2 | 13 | 7 | 6 | 10 | 37 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | 1 | 4 | 6 | 6 | 18 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | — | 1 | 1 | 3 | 3 | 8 |
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | — | — | — | 1 | — | 1 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic disease | D002908 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | 3 | — | — | — | 3 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 3 | — | — | — | 3 |
| Left ventricular dysfunction | D018487 | — | — | — | 3 | — | — | — | 3 |
| Ventricular dysfunction | D018754 | — | — | — | 3 | — | — | — | 3 |
| Interstitial lung diseases | D017563 | HP_0006530 | J84.89 | — | 2 | — | — | — | 2 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | 1 | 1 | — | — | — | 2 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 1 | — | — | — | 1 |
| Pulmonary fibrosis | D011658 | — | — | — | 1 | — | — | — | 1 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | — | — | — | 1 | 1 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | — | — | 1 | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 1 | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 1 | 1 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Riociguat |
| INN | riociguat |
| Description | Riociguat is a carbamate ester that is the methyl ester of {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamic acid. It is used for treatment of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension It has a role as a soluble guanylate cyclase activator and an antihypertensive agent. It is a pyrazolopyridine, an aminopyrimidine, an organofluorine compound and a carbamate ester. |
| Classification | Small molecule |
| Drug class | guanaline cyclase activators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N |
Identifiers
| PDB | — |
| CAS-ID | 625115-55-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107834 |
| ChEBI ID | 76018 |
| PubChem CID | — |
| DrugBank | DB08931 |
| UNII ID | RU3FE2Y4XI (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Adempas – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,458 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adempas
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,940 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use